Quick answer

The triple agonist — GLP-1, GIP, and glucagon receptors — whose phase-2 ≈−24.2% at 48 weeks set the class record. Phase 3 (TRIUMPH) decides whether it holds; nothing sold as “retatrutide” today is legitimate medicine.

ClassGLP-1/GIP/glucagon triple receptor agonist — weeklyDeveloperEli Lilly · phase 3 (TRIUMPH program)Key dataPhase 2: ≈ −24.2% at 48 wk, top dose — with the curve still descending at trial’s endMechanism logicAdds glucagon-receptor energy-expenditure effects to the incretin pairStatusNot approved; phase 3 readouts pending — verify currentBuyer noteGray-market “retatrutide” vials are the peptide-warning file’s cover story

Deeper data: the trial index holds every figure above with sources; the full preview, reading phase-2 numbers properly.

Retatrutide is the molecule people whisper about: three receptor targets, and a phase 2 average of roughly 24% weight loss at 48 weeks — numbers approaching bariatric-surgery territory, from a weekly injection that is still years from any pharmacy shelf.

The triple mechanism

To tirzepatide’s GIP + GLP-1 pairing, retatrutide adds glucagon receptor agonism — counterintuitive, since glucagon raises glucose, but its energy-expenditure and hepatic effects appear to push fat loss further. The phase 2 trial (NEJM, 2023) reported means around 24% at the top dose with weight still declining at the study’s end.

Where it stands

Phase 3 (the TRIUMPH program) was underway as of our last verification, with readouts expected on a multi-year horizon; nothing is approved, and phase 2 means are not destiny — larger trials routinely shave headline numbers. Our deeper treatment: the retatrutide preview.

The hazard around the hype

Retatrutide is among the most counterfeited names in the gray-market peptide economy — vials of unknown identity sold to people who’ve read one trial result. No compounder can legally produce it for patients; no telehealth program can prescribe it. The full warning file is here.

The numbers in context

Handle the 24% with care. It is a phase 2 mean at 48 weeks; tirzepatide’s 20.9% and semaglutide’s 14.9% are phase 3 means at 72 and 68 weeks — different trial sizes, durations, and populations. Phase 3 programs routinely land below phase 2 headlines. The defensible statement: retatrutide’s early data sits meaningfully above everything approved, and weight was still trending down when the phase 2 clock stopped — grounds for attention, not for pre-ordering.

The side-effect signal so far

Gastrointestinal effects lead, as across the class, with dose-dependent increases in heart rate reported in phase 2 — one of the parameters the phase 3 program is watching closely, and a reminder that a third receptor is a third source of physiology, not a free lunch. Cardiovascular safety characterization is precisely what large trials exist to settle.

Names you’ll encounter

Community shorthand includes “reta” and “triple G,” and the literature says “GIP/GLP-1/glucagon receptor triagonist.” Every one of those names on a vendor site is a red flag by definition — the compound exists legitimately only inside the registered TRIUMPH trials, which are searchable on ClinicalTrials.gov.

How to follow it responsibly

Three habits: read results only from the registered trials and their peer-reviewed publications rather than screenshots; expect phase 3 means to land below phase 2 headlines and plan accordingly; and treat any purchase opportunity as the scam it is until the day an FDA approval letter exists. We will update this file at each program milestone.

References

Jastreboff et al., NEJM 2023 (phase 2). Trial registry: TRIUMPH program — verify current status.